- Home
- CELU vs CALC Comparison
CELU vs CALC Comparison
Compare CELU & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- CALC
- Stock Information
- Founded
- CELU 2016
- CALC 2011
- Country
- CELU United States
- CALC United States
- Employees
- CELU N/A
- CALC N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- CALC Health Care
- Exchange
- CELU Nasdaq
- CALC Nasdaq
- Market Cap
- CELU 49.9M
- CALC 40.3M
- IPO Year
- CELU N/A
- CALC N/A
- Fundamental
- Price
- CELU $2.24
- CALC $2.74
- Analyst Decision
- CELU
- CALC Strong Buy
- Analyst Count
- CELU 0
- CALC 5
- Target Price
- CELU N/A
- CALC $18.20
- AVG Volume (30 Days)
- CELU 231.0K
- CALC 68.7K
- Earning Date
- CELU 11-07-2024
- CALC 11-13-2024
- Dividend Yield
- CELU N/A
- CALC N/A
- EPS Growth
- CELU N/A
- CALC N/A
- EPS
- CELU N/A
- CALC N/A
- Revenue
- CELU $48,200,000.00
- CALC N/A
- Revenue This Year
- CELU N/A
- CALC N/A
- Revenue Next Year
- CELU $233.89
- CALC N/A
- P/E Ratio
- CELU N/A
- CALC N/A
- Revenue Growth
- CELU 225.94
- CALC N/A
- 52 Week Low
- CELU $1.30
- CALC $2.05
- 52 Week High
- CELU $7.97
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- CELU 46.60
- CALC 32.63
- Support Level
- CELU $2.17
- CALC $2.71
- Resistance Level
- CELU $2.43
- CALC $3.27
- Average True Range (ATR)
- CELU 0.26
- CALC 0.26
- MACD
- CELU -0.01
- CALC -0.01
- Stochastic Oscillator
- CELU 54.02
- CALC 47.59
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.